This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Nemaura Medical Toekomstige groei
Future criteriumcontroles 2/6
Nemaura Medical's earnings are forecast to decline at 20.8% per annum while its annual revenue is expected to grow at 214.5% per year. EPS is expected to decline by 19.1% per annum.
Belangrijke informatie
-20.8%
Groei van de winst
-19.1%
Groei van de winst per aandeel
| Medical Equipment winstgroei | 15.8% |
| Inkomstengroei | 214.5% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 22 Feb 2024 |
Recente toekomstige groei-updates
Geen updates
Recent updates
Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 3/31/2025 | 1 | -13 | N/A | -11 | 1 |
| 3/31/2024 | 0 | -9 | N/A | -7 | 1 |
| 12/31/2023 | N/A | -11 | -10 | -10 | N/A |
| 9/30/2023 | 0 | -10 | -10 | -10 | N/A |
| 6/30/2023 | 0 | -13 | -9 | -9 | N/A |
| 3/31/2023 | 0 | -14 | -9 | -8 | N/A |
| 12/31/2022 | 0 | -13 | -9 | -8 | N/A |
| 9/30/2022 | 1 | -15 | -8 | -8 | N/A |
| 6/30/2022 | 1 | -14 | -8 | -7 | N/A |
| 3/31/2022 | 1 | -14 | -7 | -7 | N/A |
| 12/31/2021 | 0 | -12 | -7 | -6 | N/A |
| 9/30/2021 | N/A | -10 | -8 | -6 | N/A |
| 6/30/2021 | N/A | -9 | -8 | -7 | N/A |
| 3/31/2021 | N/A | -6 | -7 | -6 | N/A |
| 12/31/2020 | N/A | -5 | -6 | -6 | N/A |
| 9/30/2020 | N/A | -4 | -5 | -5 | N/A |
| 6/30/2020 | N/A | -4 | -4 | -4 | N/A |
| 3/31/2020 | N/A | -4 | -4 | -3 | N/A |
| 12/31/2019 | N/A | -4 | -4 | -4 | N/A |
| 9/30/2019 | N/A | -5 | -4 | -4 | N/A |
| 6/30/2019 | N/A | -5 | -4 | -4 | N/A |
| 3/31/2019 | N/A | -4 | -4 | -4 | N/A |
| 12/31/2018 | N/A | -3 | -3 | -3 | N/A |
| 9/30/2018 | N/A | -3 | -3 | -3 | N/A |
| 6/30/2018 | N/A | -2 | -2 | -2 | N/A |
| 3/31/2018 | N/A | -2 | -2 | -2 | N/A |
| 12/31/2017 | N/A | -2 | -2 | -2 | N/A |
| 9/30/2017 | N/A | -2 | N/A | -2 | N/A |
| 6/30/2017 | N/A | -1 | N/A | -1 | N/A |
| 3/31/2017 | N/A | -2 | N/A | -1 | N/A |
| 12/31/2016 | N/A | -2 | N/A | -1 | N/A |
| 9/30/2016 | N/A | -2 | N/A | -1 | N/A |
| 6/30/2016 | N/A | -2 | N/A | -1 | N/A |
| 3/31/2016 | N/A | -2 | N/A | -1 | N/A |
| 12/31/2015 | N/A | -2 | N/A | -1 | N/A |
| 9/30/2015 | N/A | -1 | N/A | -1 | N/A |
| 6/30/2015 | N/A | -1 | N/A | -1 | N/A |
| 3/31/2015 | N/A | -1 | N/A | -1 | N/A |
| 12/31/2014 | N/A | -1 | N/A | 0 | N/A |
| 9/30/2014 | N/A | -1 | N/A | 1 | N/A |
| 6/30/2014 | N/A | -1 | N/A | 1 | N/A |
| 3/31/2014 | N/A | -1 | N/A | 2 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: N18A is forecast to remain unprofitable over the next 3 years.
Winst versus markt: N18A is forecast to remain unprofitable over the next 3 years.
Hoge groeiwinsten: N18A is forecast to remain unprofitable over the next 3 years.
Omzet versus markt: N18A's revenue (214.5% per year) is forecast to grow faster than the German market (5.5% per year).
Hoge groei-inkomsten: N18A's revenue (214.5% per year) is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if N18A's Return on Equity is forecast to be high in 3 years time